Targeting Transcriptional Dysregulation in Huntington’s Disease: Description of Therapeutic Approaches

Basso, Manuela

doi:10.5772/31579

Huntington's Disease - Core Concepts and Current Advances 2012

DOI: 10.5772/31579

|View full text |Cite

Targeting Transcriptional Dysregulation in Huntington’s Disease: Description of Therapeutic Approaches

Manuela Basso¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders

2017

View full text Add to dashboard Cite

Long term suppression of succinate dehydrogenase by selective inhibitor 3-nitropropionic acid has been used in rodents to model Huntington's disease where mitochondrial dysfunction and oxidative damages are primary pathological hallmarks for neuronal damage. Improvements in learning and memory abilities, recovery of energy levels, and reduction of excitotoxicity damage can be achieved through activation of Adenyl cyclase enzyme by a specific phytochemical forskolin. In this study, intraperitoneal administration of 10 mg/kg 3-nitropropionic acid for 15 days in rats notably reduced body weight, worsened motor cocordination (grip strength, beam crossing task, locomotor activity), resulted in learning and memory deficits, greatly increased acetylcholinesterase, lactate dehydrogenase, nitrite, and malondialdehyde levels, obviously decreased adenosine triphosphate, succinate dehydrogenase, superoxide dismutase, catalase, and reduced glutathione levels in the striatum, cortex and hippocampus. Intragastric administration of forskolin at 10, 20, 30 mg/kg dose-dependently reversed these behavioral, biochemical and pathological changes caused by 3-nitropropionic acid. These results suggest that forskolin exhibits neuroprotective effects on 3-nitropropionic acid-induced Huntington's disease-like neurodegeneration.

show abstract

Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders

2017

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Targeting Transcriptional Dysregulation in Huntington’s Disease: Description of Therapeutic Approaches

Cited by 1 publication

References 87 publications

Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders

Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders

Contact Info

Product

Resources

About